Polyrizon Ltd. (Nasdaq: PLRZ), a development stage biotech company, has announced positive preclinical data for its nasal protection platform. The company conducted ex vivo studies in collaboration with Prof. Fabio Sonvico's laboratory, utilizing excised rabbit nasal mucosa to assess the surface coverage and mucoadhesive performance of its proprietary intranasal hydrogel formulation. The studies demonstrated that Polyrizon's formulation rapidly spreads and uniformly covers the nasal mucosa, forming a consistent surface layer. The formulation also exhibited strong and lasting mucoadhesion, even under simulated physiological nasal fluid flow conditions. These findings suggest the potential for effective localized protection or therapeutic delivery, enhancing the formulation's potential efficacy in real-world scenarios.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。